Undisclosed RNA-based immunotherapy
/ Epitopea
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 24, 2024
Epitopea Closes USD $31 million Pre-Series A Financing
(GlobeNewswire)
- "Epitopea...announces the closing of a USD $31 million pre-Series A financing...'This pre-Series A raise provides the necessary finances to accelerate our development campaigns and transition to a clinical-stage company with a focused commitment of delivering our transformational RNA cancer immunotherapy into the clinic in 2026,'..."
Financing • Oncology
1 to 1
Of
1
Go to page
1